Segment Reporting Disclosure [Text Block] | 10 . Operating Segments In accordance with ASC 280, may 2 3 Our reporting segments are defined as below: TREATMENT SEGMENT reporting includes: - nuclear, low-level radioactive, mixed, hazardous and non-hazardous waste treatment, processing and disposal services primarily through four - R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams. SERVICES SEGMENT, which includes: - On-site waste management services to commercial and government customers; - Technical services, which include: o professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering; o integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance; o global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; - Nuclear services, which include: o technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal; o remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; site construction; logistics; transportation; and emergency response; and - A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) of health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation. MEDICAL SEGMENT reporting includes: R&D costs for the new medical isotope production technology from our majority-owned Polish subsidiary, PF Medical. The Medical Segment has not All costs incurred for the Medical Segment are reflected within R&D in the accompanying Consolidated Statements of Operations and consist primarily of employee salaries and benefits, laboratory costs, third Our reporting segments exclude our corporate headquarters and our discontinued operations (see Note 9 not The table below presents certain financial information of our operating segments for the three six June 30, 2017 2016 Segment Reporting for the Quarter Ended June 30, 2017 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 9,630 $ 3,085 — $ 12,715 $ — $ 12,715 Intercompany revenues 97 7 — 104 — — Gross profit 2,174 180 — 2,354 — 2,354 Research and development 62 — 550 612 7 619 Interest income — — — — 36 36 Interest expense (18 ) — — (18 ) (72 ) (90 ) Interest expense-financing fees — — — — (9 ) (9 ) Depreciation and amortization 988 135 — 1,123 10 1,133 Segment income (loss) before income taxes 1,238 (553 ) (550 ) 135 (1,295 ) (1,160 ) Income tax expense 65 — — 65 1 66 Segment income (loss) 1,173 (553 ) (550 ) 70 (1,296 ) (1,226 ) Expenditures for segment assets 91 3 — 94 — 94 Segment Reporting for the Quarter Ended June 30, 2016 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 7,985 $ 6,824 — $ 14,809 $ — $ 14,809 Intercompany revenues 6 10 — 16 — — Gross profit 582 1,234 — 1,816 — 1,816 Research and development 120 7 416 543 11 554 Interest income 2 — — 2 29 31 Interest expense (14 ) — — (14 ) (94 ) (108 ) Interest expense-financing fees — — — — (29 ) (29 ) Depreciation and amortization 705 160 — 865 47 912 Segment (loss) income before income taxes (10,557 ) (2) 1,046 (416 ) (9,927 ) (1,374 ) (11,301 ) Income tax benefit (3,167 ) (2) — — (3,167 ) — (3,167 ) Segment (loss) income (7,390 ) 1,046 (416 ) (6,760 ) (1,374 ) (8,134 ) Expenditures for segment assets 16 4 — 20 — 20 Segment Reporting for the Six Months Ended June 30, 2017 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 19,665 $ 5,757 — $ 25,422 $ — $ 25,422 Intercompany revenues 113 10 — 123 — — Gross profit 4,861 212 — 5,073 — 5,073 Research and development 243 — 750 993 15 1,008 Interest income — — — — 71 71 Interest expense (26 ) (1 ) — (27 ) (162 ) (189 ) Interest expense-financing fees — — — — (18 ) (18 ) Depreciation and amortization 1,997 271 — 2,268 20 2,288 Segment income (loss) before income taxes 2,840 (1,260 ) (750 ) 830 (2,584 ) (1,754 ) Income tax expense 145 — — 145 2 147 Segment income (loss) 2,695 (1,260 ) (750 ) 685 (2,586 ) (1,901 ) Expenditures for segment assets 106 10 — 116 — 116 Segment Reporting for the Six Months Ended June 30, 2016 Treatment Services Medical Segments Total Corporate (1) Consolidated Total Revenue from external customers $ 15,189 $ 9,658 — $ 24,847 $ — $ 24,847 Intercompany revenues 10 15 — 25 — — Gross profit 444 1,406 — 1,850 — 1,850 Research and development 226 33 854 1,113 15 1,128 Interest income 2 — — 2 45 47 Interest expense (16 ) — — (16 ) (260 ) (276 ) Interest expense-financing fees — — — — (85 ) (85 ) Depreciation and amortization 1,418 321 — 1,739 57 1,796 Segment (loss) income before income taxes (11,805 ) (2) 322 (854 ) (12,337 ) (2,773 ) (15,110 ) Income tax benefit (3,130 ) (2) — — (3,130 ) — (3,130 ) Segment (loss) income (8,675 ) 322 (854 ) (9,207 ) (2,773 ) (11,980 ) Expenditures for segment assets 23 4 1 28 — 28 ( 1 ) not ( 2 ) $1,816,000 $8,288,000, $3,203,000 |